Investment analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Up 2.3 %
LPCN opened at $5.44 on Friday. The firm has a market cap of $28.94 million, a PE ratio of -1.78 and a beta of 1.05. The business has a fifty day simple moving average of $4.45 and a 200-day simple moving average of $3.46. Lipocine has a fifty-two week low of $2.31 and a fifty-two week high of $7.15.
Lipocine (NASDAQ:LPCN – Get Free Report) last announced its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.11. The company had revenue of $0.22 million for the quarter. On average, equities research analysts anticipate that Lipocine will post -1.49 EPS for the current fiscal year.
Institutional Investors Weigh In On Lipocine
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Recommended Stories
- Five stocks we like better than Lipocine
- 3 Healthcare Dividend Stocks to Buy
- Comprehensive PepsiCo Stock Analysis
- How to Invest in the Best Canadian StocksĀ
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is the Shanghai Stock Exchange Composite Index?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.